Honors & Awards

  • Research Funding Grant, CHRI: Tashia and John Morgridge Endowed Postdoctoral Fellow (2014-2016)

Boards, Advisory Committees, Professional Organizations

  • Member, NASPGHAN: North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (2013 - Present)
  • Former National Resident President, American Medical Women's Association (2010 - 2011)
  • Member, American Academy of Pediatrics (2010 - Present)

Professional Education

  • Pediatric GI Fellow, Lucile Packard Children's Hospital Stanford, Pediatric Gastroenterology, Hepatology, and Nutrition (2013)
  • Pediatric Resident, Penn State University Hershey Medical Center, Pediatric Internship & Residency (2013)
  • Doctor of Medicine, Florida State University (2010)
  • Clinical & Bench Research Fellow, National Institutes of Health - National Institute of Child Health and Human Development (2007)
  • Lieutenant, United States Navy Reserves, Pediatric Gastroenterology (2010)
  • Senior Research Fellow, H. Lee Moffitt Cancer Center & Research Institute, Clinical Research (2006)
  • Bachelor of Science, University of Florida (2005)

Stanford Advisors


  • A Novel Preparation of Fecal Microbiota Transplant in Recurrent Pediatric C Difficile Infection, Stanford, Lucile Packard Children's Hospital (July 1, 2014 - Present)

    Recurrent Clostridium difficile infection (CDI) is a serious cause of morbidity in pediatrics. Oral Vancomycin, per standard of care, fails 1/3 of patients who develop relapses due to a perturbed bacterial milleu in the gut. A promising therapy emerged in the adult literature called Fecal Microbiota Transplant (FMT) whereby stool from a healthy donor is transplanted into a CDI patient to correct this dysbiosis; studies have shown >90% efficacy. The Food and Drug Administration has recognized the importance of availability of FMT and issued an Investigational New Drug (IND) exemption to bring FMT to patients in need of intervention for their life-haulting symptoms of diarrhea and poor quality of life. Due to logistical burden, technical inexperience, and lack of a standardized protocol for pediatrics, however, very few pediatric centers perform FMT. LPCH has established a novel “universal frozen” protocol adherent to FDA safety requirements which streamlines the process by identifying a universal donor and keeping frozen ready-to-use transplant material (TM) on hand. Based on successful studies in adults, this pilot will determine the effectiveness of FMT with the frozen TM. In this pilot investigation, we use an observational prospective cohort study design with a translational component using high throughput sequencing.


    Palo Alto, CA, USA


All Publications

  • Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping BREAST JOURNAL Khera, S. Y., Kiluk, J. V., Hasson, D. M., Meade, T. L., Meyers, M. P., Dupont, E. L., Berman, C. G., Cox, C. E. 2008; 14 (3): 250-254


    As more women put off pregnancy until their 30s and beyond, the possibility of pregnancy-associated breast cancer (PABC) will rise. Treatment options for patients with PABC need to consider possible harm to the fetus. The goal of this study is to review our institution's experience with sentinel lymph node (SLN) biopsies in patients with PABC. A prospectively accrued breast Institutional Review Board (IRB) approved data base was searched under separate IRB approval for cases of SLN biopsy in patients with PABC. Ten patients were identified between 1994 and 2006 out of 5,563 patients. A chart review was performed on all 10 patients. Ten patients with PABC and an average gestation age of 15.8 weeks underwent SLN biopsy. All patients successfully mapped. Positive SLN were identified in 5/10 patients (50%) while there was no evidence of metastases in 5/10 patients (50%). 9/10 (90%) of patients went on to deliver healthy children without any reported problems. One patient (10%) decided to terminate her pregnancy in the first trimester following surgery prior to the start of chemotherapy. SLN biopsy can safely be performed in patients with PABC with minimal risk to the fetus. By performing a SLN biopsy, a large proportion of patients with PABC may be spared the risk of a complete axillary lymph node dissection.

    View details for Web of Science ID 000255725400006

    View details for PubMedID 18476883

  • Problems with the use of breast conservation therapy for breast cancer in a patient with neurofibromatosis type 1: A case report BREAST JOURNAL Hasson, D. M., Khera, S. Y., Meade, T. L., Dupont, E. L., Greenberg, H. M., Diaz, N. M., Romilly, A. P., Cox, C. E. 2008; 14 (2): 188-192


    Patients with neurofibromatosis type I and breast cancer represent a subset of people who may be considered at high risk for secondary cancers after conventional whole breast radiation therapy and breast conservation surgery. A case of a 49-year-old woman with neurofibromatosis type I is presented. She was diagnosed with a 1.1-cm right breast infiltrating ductal carcinoma. Clinical, diagnostic imaging, and pathologic features are discussed. Her initial treatment plan of breast conserving therapy was thwarted when her sentinel node biopsy was positive for micrometastatic disease in 1/14 lymph nodes. She elected to have a bilateral simple mastectomy. This case addresses the rare dilemma of offering breast conservation therapy as a viable option for patients with neurofibromatosis type I. Current data on radiation-induced secondary cancers such as sarcoma after treatment for breast and other cancers are reviewed.

    View details for Web of Science ID 000253712200012

    View details for PubMedID 18248558

  • Violence in Women: Awareness, Advocacy, Action Family Medicine Digital Resource Library Danielle, B., Elizabeth, B., Lauren, E., Christina, M., Jaqueline, T., Marjorie, W., Tiffany, W., Suzanne, H. 2008
  • Sentinel Lymph Node Biopsy in Patients with Breast Cancer Radioguided Surgery Charles, C. E., Danielle, H. M., John, C. M., Caren, W., Laura, W., Samira, K. 2008
  • Paget's disease in the era of sentinel lymph node biopsy AMERICAN JOURNAL OF SURGERY Laronga, C., Hasson, D., Hoover, S., Cox, J., Cantor, A., Cox, C., Carter, W. B. 2006; 192 (4): 481-483


    Paget's disease of the breast is an uncommon cancer. "Breast cancer" management has evolved to include sentinel lymph node biopsy (SLNB). Our objective is to determine utilization of SLNB in the surgical algorithm of Paget's disease.After institutional review board approval, a database review of patients with Paget's disease was conducted. Patient demographics, tumor characteristics, treatment including use of SLNB, and survival were reviewed. Patient characteristics and outcomes were analyzed by using contingency table chi-square, pooled t tests, and log-rank tests for comparisons.Fifty-four patients with Paget's disease were identified and divided into 2 cohorts (18 no SLNB and 36 SLNB). The mean age was 66 years for the no-SLNB group and 60 years for the SLNB group (P = .17). Paget's disease only was present in 33%, Paget's disease + DCIS in 41%, and Paget's disease + invasive cancer in 26%. The mean invasive tumor size was 1.62 cm in the no-SLNB group and 1.59 cm in the SLNB group (P = .96). For invasive disease, ER/PR status was similar, but Her2 was more likely to be overexpressed in SLNB (P = .04). Surgery choice ranged from "no surgery" to lumpectomy to mastectomy. Axillary staging was performed in 45 of 54 patients, with 11% in both cohorts having nodal disease. A sentinel lymph node was identified in 97% of patients. Five-year overall and disease-free survival was 100% in the no-SLNB group and 88% in the SLNB group (P = .97) and 76% in the no-SLNB group and 84% in the SLNB group (P = .88), respectively.Paget's disease remains rare but should be treated similar to other "breast cancer." SLNB should be performed to evaluate the axilla when invasive disease is identified or a mastectomy is planned.

    View details for DOI 10.1016/j.amjsurg.2006.06.023

    View details for Web of Science ID 000240750800016

    View details for PubMedID 16978954